GO
Loading...

Cramer Smells Opportunity in Biopharma

"If you're going to speculate on pharma stocks, ideally you don't just want a company that's a one drug wonder," said Jim Cramer, you want a company with multiple shots on goal."

That's why Cramer like Alkermes (TICKER:ALKS), a biopharma play that specializes in taking existing drugs, and creating long-acting formulations that are easier for patients to take.

Following are a few of their drugs:

- Bydureon: a diabetes drug that only needs to be injected once a week.

- Vivitrol: a once-monthly injection that helps treat alcoholism and opioid addiction.

- Risperdal Consta: an anti-psychotic franchise in partnership with Johnson & Johnson, that helps treat people with severe mental illnesses like schizophrenia.


Adam Jeffery | CNBC

And Cramer sees more reason to like this stock.

Alkermes is currently working on a new extended release version of Abilify, the incredibly popular $7 billion anti-psychotic drug from Bristol-Myers.

"The Alkermes version would only have to be injected once a month, rather than making people remember to swallow a pill once or twice a day. We should get phase 3 results on this one later this year," he said.

It's worth noting that rival Otsuka is working on a once-a-month injectable form of the very same drug, and they could get FDA approval as soon as this week.

"Although I'm worried about the potential for competition here, there's another school of thought that says Otsuka getting FDA approval would validate Alkermes' approach," Cramer explained .

---------------------------------------------------------
Read More from Mad Money with Jim Cramer:
Cramer: Don't Get Distracted
This Housing Spec Is a Steal: Cramer
Coke or Pepsi: Which Does Cramer Prefer?
---------------------------------------------------------

Looking at the price action, Cramer sees another reason to feel bullish.

"Alkermes has had a nice run. That said, the company reported a fabulous quarter at the end of January where they raised guidance for the third time in a row, and after initially spiking up to $23, the stock is now trading below where it was when that earnings report came out,' Cramer said.

The diagnosis?

When you take the current pipeline, the new drug potential and the price action Cramer said "It smells like an opportunity to me."

Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com

Symbol
Price
 
Change
%Change
ALKS
---
XLV
---

Featured

Contact Mad Money

  • Showtimes

    U.S.
    Monday - Friday 6p ET
    Australia
    Saturday 8a, 1p, 7p SYD
    Sunday 12a, 1a, 8a, 7p SYD
    New Zealand
    Saturday 10a, 3p, 9p NZ
    Sunday 2a, 3a, 10a, 9p NZ
  • Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.

Cramer's New Book